We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Bonnie J. Addario Lung Cancer Foundation (BJALCF) Announces 2011 Grants Worth over $1 Million
News

Bonnie J. Addario Lung Cancer Foundation (BJALCF) Announces 2011 Grants Worth over $1 Million

Bonnie J. Addario Lung Cancer Foundation (BJALCF) Announces 2011 Grants Worth over $1 Million
News

Bonnie J. Addario Lung Cancer Foundation (BJALCF) Announces 2011 Grants Worth over $1 Million

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Bonnie J. Addario Lung Cancer Foundation (BJALCF) Announces 2011 Grants Worth over $1 Million"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Just ask any one of the BJALCF Lung Cancer survivors, family members or friends fighting for survival--or any of those who have lost someone they love way too soon to this horrific and most-underfunded #1 Cancer Killer, why results-oriented projects are of the essence? BJALCF's ultimate goal is to turn Lung Cancer into a survivable, manageable chronic disease. After rigorous review of 26 grant requests by the BJALCF Scientific Advisory Board, much-needed funding has been distributed worldwide to the brightest, most dedicated, and determined researchers in the urgent quest to extend lives. They are as follows:

Guoan Chen, PhD, assistant research professor in Thoracic Oncology at University of Michigan in Ann Arbor, Michigan for the "Discovery and Validation of Serum Micro-RNAs for Lung Cancer Diagnosis and Prognosis" with the primary objective to detect Lung Cancer earlier and significantly reduce the mortality of NSCLC.

Rolf Craven, PhD, associate professor, Department of Molecular and Biomedical Pharmacology at Markey Cancer Center College of Medicine in Lexington, Kentucky for "S2R (Pgrmc1): sigma-2 receptor as a therapeutic target in Lung Cancer" with the primary objective to develop new therapeutic and diagnostic strategies for erlotinib-resistant Lung Cancer.

Carlo Maley, PhD, associate professor and director of the Center for Evolution and Cancer at the University of California, San Francisco (UCSF) and Natalie Lui, MD, a surgery resident in the Thoracic Oncology Program in the Department of Surgery at UCSF, for "Within Tumor Genetic Diversity in Lung Cancer" with the primary objective to determine whether genetic diversity at treatment predicts survival in patients with adenocarcinoma, ultimately leading to a greater understanding of Lung Cancer's response to therapy and a new method for predicting survival.

Jiantao Pu, PhD, assistant professor at the University of Pittsburgh School of Medicine for "Diagnosis-by-Search: Enabling Early Detection & Accurate Diagnosis of Lung Cancer" with the primary objective to develop a novel computer-aided diagnosis paradigm leading to a significant reduction of Lung Cancer mortality.

Advertisement